A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND# 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)

About this Study

This pilot study is testing the drug rituximab and immune cells from donors to treat post-transplant lymphoproliferative disease in people after solid organ transplant.

Sponsor Protocol ID:ANHL1522
IRB Number:2017-0307
Actively Enrolling
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
30 years old
Both Male and Female
No
Yes
No

Inclusion CriteriaNone.

Exclusion Criteria
  • Pregnancy and Breast Feeding.

Categories Click category to view its trials.
Pediatrics
Surgery
Transplant
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Maggie Goad
Phone Number: 601-815-9390
Email: mgoad@umc.edu
Principal Investigator:Betty H Melton
How to participate in our Clinical Trials